Proactive Investors - Run By Investors For Investors

ImmuPharma says article shines light on potential of peptide subsidiary

Peptide drugs generated US$30bn in sales last year
Scientist pouring liquid into test tube
The work of the Ureka began in 2014 and the ImmuPharma offshoot has a tie-up with France’s Centre National de la Recherche Scientifique

ImmuPharma PLC (LON:IMM) said peer-reviewed journal Nature Communications has carried an article assessing the potential of Urelix, a technology developed by its subsidiary Ureka.

The periodical has described for the first time the unique properties of oligourea foldamers as tools to improve the pharmaceutical properties of peptides.

There are more than 7,000 naturally occurring peptides that have crucial roles in human physiology, including actions as hormones, neurotransmitters and growth factors.

Around 140 peptide therapeutics are currently being developed, while currently around 60 have been approved by the US Food & Drug Administration generating sales last year of US$30bn.

However, as Dimitri Dimitriou, ImmuPharma's chief executive, pointed out: “Using natural peptides as drugs is not so effective because they are quickly broken down. 

“To put it simply, our technology overcomes these challenges and represents an intelligent way to design novel drugs.”

One of the first areas of focus for the Ureka researchers has been lookalikes for GLP-1, the basis of a number of drugs used to treat type II diabetes and non-alcoholic liver disease.

Scientists are also assessing the potential of using the Urelix to develop cancer drug candidates and as means of improving products already on the market.

The work of the Ureka began in 2014 and the ImmuPharma offshoot has a tie-up with France’s Centre National de la Recherche Scientifique.

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
genedrive device
May 23 2019
Here we take a closer look at Genedrive PLC (LON:GDR)
consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use